remdesivir

Gilead Sciences, Inc. (NASDAQ: GILD) recently received emergency use authorization from the FDA for its coronavirus treatment candidate remdesivir. The company now faces a conundrum: either mass produce the drug to satisfy the rising global demand or license the drug to others,...

Gilead Sciences Inc's (NASDAQ: GILD) remdesivir has been granted U.S. Food and Drug Administration emergency use for the treatment of the coronavirus (COVID-19). Vice President Mike Pence announced 1 million vials of remdesivir will be distributed to hospitals on Monday. The FDA Emergency use...

Gilead Sciences, Inc. (NASDAQ: GILD) reported an earnings and sales beat Thursday, but apprehension surrounding the drugmaker's remdesivir, under evaluation as a potential COVID-19 treatment, are weighing down on the stock. The Gilead Analysts Wells Fargo Securities analyst Jim...

Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Gilead’s Big Decade One strong...

The much-awaited results of U.S. trial of Gilead Sciences, Inc.'s (NASDAQ: GILD) investigational antiviral therapy remdesivir in treating coronavirus infection arrived Wednesday.  The Forest City, California-based company said it is "aware" that the National Institute of...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) fell Thursday afternoon in reaction to a disappointing report on an early readout for its remdesivir therapy, but investors should not "give up on this drug," Baird analyst Brian Skorney said on CNBC's "Closing Bell." The...

Gilead Sciences, Inc. (NASDAQ: GILD) shares were trading lower Thursday after the Financial Times reported that the company ended a study on remdesivir in coronavirus in China due to low enrollment and said study results were inconclusive. Gilead took issue with the...

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...

Former FDA Commissioner Dr. Scott Gottlieb spoke on CNBC Thursday about Gilead's (NASDAQ: GILD) remdesivir trial. Enough data is likely accumulated at this point that the regulatory agency might consider making the drug available under the emergency use authorization or through...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) gained more than 15% after Thursday's market close and the encouraging report from STAT is "good news" although anecdotal, CNBC's Guy Adami said. The report is encouraging from a human point of view as keeping people safe is...

Gilead Sciences, Inc. (NASDAQ: GILD) announced publication Friday of data in the New England Journal of Medicine from a small cohort of COVID-19 patients who were treated with its remdesivir through compassionate use. The Gilead Analysts BofA Securities analyst Geoff Meacham maintained...

The world is waiting with baited breath for the outcome of two late-stage studies underway in China for Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir as a potential COVID-19 treatment. The Gilead Analyst Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Gilead...

Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir is one of the frontrunners among investigational drugs to treat COVID-19. With a data readout imminent and following an update from CEO Daniel O'Day, an analyst at Cantor Fitzgerald looked at what could lie ahead for the company with...

The U.S. took a step forward in its battle against the coronavirus pandemic by taking steps to eventually slow the spread of the virus, former FDA head Scott Gottlieb said Friday evening on CNBC. What Happened April will prove to be a "tough month," but the country is prepared to "...

A senior research analyst at Piper Sandler believes Gilead Sciences Inc.'s (NASDAQ: GILD) Remdesivir antiviral may soon be approved for COVID-19 treatment. The Gilead Analyst Tyler Van Buren maintains a Neutral rating on Gilead with a price target of $70. The Gilead Thesis Remdesivir has been...